Johnson & Johnson Insider Trading

JNJ

Last 12 months

Insiders bought 258K and sold $151M on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. CEO and Chairman of the Board Joaquin Duato sold $32.2M on Aug 13, 29% of their stake, outside a plan.

Net open-market

−$150M

1 buy · 15 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 10

executives and directors

Last open-market buy

Nov 2025

Nov 26, 2025

Get an email when JNJ's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 2	Timothy Schmid EVP, WW Chair, MedTech	SoldNo plan 2 parts	33,597	$274.74 average	$9.23M	56%	Form 4
Aug 17	Jennifer L Taubert EVP, WWC. Innovative Medicine	SoldNo plan	15,000	$263.36	$3.95M	7.2%	Form 4
Aug 13	Joaquin Duato CEO and Chairman of the Board	SoldNo plan 2 parts	123,291	$261.17 average	$32.2M	29%	Form 4
Aug 6	Elizabeth Forminard EVP, Chief Legal Officer	SoldNo plan 2 parts	15,918	$257.00 average	$4.09M	48%	Form 4
Aug 5	Joaquin Duato CEO and Chairman of the Board	SoldNo plan 2 parts	48,480	$258.15 average	$12.5M	14%	Form 4
Jul 20	Vanessa Broadhurst EVP, Global Corp Affairs	SoldNo plan	23,054	$251.27	$5.79M	50%	Form 4
Jun 11	Kathryn E Wengel EVP, Chief TO and Risk Officer	SoldNo plan	10,000	$241.15	$2.41M	8.0%	Form 4
Feb 27	Robert J Decker VP Corporate Controller	SoldNo plan	4,075	$247.87	$1.01M	14%	Form 4
Feb 20	Timothy Schmid EVP, WW Chair, MedTech	SoldNo plan	1,322	$245.66	325K	4.8%	Form 4
Feb 18	Timothy Schmid EVP, WW Chair, MedTech	SoldNo plan 2 parts	22,623	$244.33 average	$5.53M	45%	Form 4
Feb 13 – 17	James D. Swanson EVP, CIO	SoldNo plan 3 parts	62,080	$243.39 average	$15.1M	71%	Form 4
Feb 17	Joseph J Wolk Exec VP, CFO	SoldNo plan 4 parts	89,654	$242.80 average	$21.8M	51%	Form 4
Feb 17	John C Reed EVP, Innovative Medicine, R&D	SoldNo plan 3 parts	53,931	$243.00 average	$13.1M	83%	Form 4
Feb 17	Vanessa Broadhurst EVP, Global Corp Affairs	SoldNo plan	6,197	$243.39	$1.51M	21%	Form 4
Jan 26	Joaquin Duato CEO and Chairman of the Board	SoldNo plan 2 parts	100,000	$221.23 average	$22.1M	25%	Form 4
Nov 26, 2025	John G Morikis Director	Bought	1,250	$206.15	258K	209%	Form 4
Oct 17, 2025	John C Reed EVP, Innovative Medicine, R&D	SoldNo plan	21,721	$192.71	$4.19M	67%	Form 4
Sep 4, 2025	Jennifer L Taubert EVP, WWC. Innovative Medicine	SoldNo plan	56,471	$177.81	$10M	24%	Form 4
Aug 22, 2025	Joaquin Duato CEO and Chairman of the Board	SoldNo plan	125,824	$179.21	$22.5M	24%	Form 4
Aug 15, 2025	Joseph J Wolk Exec VP, CFO	SoldNo plan	16,820	$176.91	$2.98M	17%	Form 4
Jul 17, 2025	John C Reed EVP, Innovative Medicine, R&D	SoldNo plan	19,137	$163.55	$3.13M	64%	Form 4
Feb 25, 2025	Robert J Decker VP Corporate Controller	SoldNo plan	6,999	$165.88	$1.16M	24%	Form 4
Feb 18, 2025	Timothy Schmid EVP, WW Chair, MedTech	SoldNo plan	403	$156.15	63K	2.6%	Form 4
Feb 7, 2025	Joseph J Wolk Exec VP, CFO	SoldNo plan	13,015	$153.89	$2M	16%	Form 4
Dec 12, 2024	Mark A Weinberger Director	Bought	1,000	$147.22	147K	New	Form 4

Sep 2No plan
Timothy Schmid
EVP, WW Chair, MedTech · sold 33,597 at avg $274.74
$9.23M
56% of stake
Aug 17No plan
Jennifer L Taubert
EVP, WWC. Innovative Medicine · sold 15,000 at $263.36
$3.95M
7.2% of stake
Aug 13No plan
Joaquin Duato
CEO and Chairman of the Board · sold 123,291 at avg $261.17
$32.2M
29% of stake
Aug 6No plan
Elizabeth Forminard
EVP, Chief Legal Officer · sold 15,918 at avg $257.00
$4.09M
48% of stake
Aug 5No plan
Joaquin Duato
CEO and Chairman of the Board · sold 48,480 at avg $258.15
$12.5M
14% of stake
Jul 20No plan
Vanessa Broadhurst
EVP, Global Corp Affairs · sold 23,054 at $251.27
$5.79M
50% of stake
Jun 11No plan
Kathryn E Wengel
EVP, Chief TO and Risk Officer · sold 10,000 at $241.15
$2.41M
8.0% of stake
Feb 27No plan
Robert J Decker
VP Corporate Controller · sold 4,075 at $247.87
$1.01M
14% of stake
Feb 20No plan
Timothy Schmid
EVP, WW Chair, MedTech · sold 1,322 at $245.66
325K
4.8% of stake
Feb 18No plan
Timothy Schmid
EVP, WW Chair, MedTech · sold 22,623 at avg $244.33
$5.53M
45% of stake
Feb 13 – 17No plan
James D. Swanson
EVP, CIO · sold 62,080 at avg $243.39
$15.1M
71% of stake
Feb 17No plan
Joseph J Wolk
Exec VP, CFO · sold 89,654 at avg $242.80
$21.8M
51% of stake
Feb 17No plan
John C Reed
EVP, Innovative Medicine, R&D · sold 53,931 at avg $243.00
$13.1M
83% of stake
Feb 17No plan
Vanessa Broadhurst
EVP, Global Corp Affairs · sold 6,197 at $243.39
$1.51M
21% of stake
Jan 26No plan
Joaquin Duato
CEO and Chairman of the Board · sold 100,000 at avg $221.23
$22.1M
25% of stake
Nov 26, 2025
John G Morikis
Director · bought 1,250 at $206.15
258K
209% of stake
Oct 17, 2025No plan
John C Reed
EVP, Innovative Medicine, R&D · sold 21,721 at $192.71
$4.19M
67% of stake
Sep 4, 2025No plan
Jennifer L Taubert
EVP, WWC. Innovative Medicine · sold 56,471 at $177.81
$10M
24% of stake
Aug 22, 2025No plan
Joaquin Duato
CEO and Chairman of the Board · sold 125,824 at $179.21
$22.5M
24% of stake
Aug 15, 2025No plan
Joseph J Wolk
Exec VP, CFO · sold 16,820 at $176.91
$2.98M
17% of stake
Jul 17, 2025No plan
John C Reed
EVP, Innovative Medicine, R&D · sold 19,137 at $163.55
$3.13M
64% of stake
Feb 25, 2025No plan
Robert J Decker
VP Corporate Controller · sold 6,999 at $165.88
$1.16M
24% of stake
Feb 18, 2025No plan
Timothy Schmid
EVP, WW Chair, MedTech · sold 403 at $156.15
63K
2.6% of stake
Feb 7, 2025No plan
Joseph J Wolk
Exec VP, CFO · sold 13,015 at $153.89
$2M
16% of stake
Dec 12, 2024
Mark A Weinberger
Director · bought 1,000 at $147.22
147K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch JNJ, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with JNJ

CompareIntrinsic value

LLYEli Lilly and Company

$1,418.07+0.62%73

MRKMerck & Co., Inc.

$150.36+3.93%41

ABBVAbbVie Inc.

$294.83+3.09%49

PFEPfizer Inc.

$30.79+2.63%30

BMYBristol-Myers Squibb Company

$64.20+4.04%61

ABTAbbott Laboratories

$115.55+5.62%25

UPCUniverse Pharmaceuticals Inc.

$1.47-1.34%39

TEVATeva Pharmaceutical Industries Ltd

$42.13+0.52%46

Held by ETFs

JNJ is in 485 US ETFs. The largest of them, with JNJ's weight in each:

Spot a number that looks wrong? Check it in JNJ's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing JNJ

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.